Send to a Friend Font Size: Increase Decrease

MDGL and ARWR Related Headlines

May 5, 2026 08:03AM Arrowhead licenses liver disease drug to Madrigal for $25 million upfront
May 5, 2026 08:00AM Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

MDGL and ARWR Related Press Releases

May 5, 2026 08:00AM Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

MDGL and ARWR Related SEC Filings